Lewy Body Dementia clinical trials at UCSD
2 in progress, 0 open to eligible people
Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Sorry, not currently recruiting here
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
La Jolla, California and other locations
Diagnostic Test for Dementia With Lewy Bodies
Sorry, in progress, not accepting new patients
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
La Jolla, California and other locations
Our lead scientists for Lewy Body Dementia research studies include Stephanie Lessig.
Last updated: